Exploring QSARs for Inhibitory Activity of Non-peptide HIV-1 Protease Inhibitors by GA-PLS and GA-SVM

被引:19
作者
Deeb, Omar [1 ]
Goodarzi, Mohammad [2 ,3 ]
机构
[1] Al Quds Univ, Fac Pharm, Jerusalem, Israel
[2] Islamic Azad Univ, Fac Sci, Dept Chem, Arak, Markazi, Iran
[3] Islamic Azad Univ, Arak Branch, Arak, Markazi, Iran
关键词
inhibitory activity; HIV-1 protease inhibitors; quantitative structure activity relationship; support vector machine; partial least square; genetic algorithms; SUPPORT VECTOR MACHINES; PARTIAL LEAST-SQUARES; GENETIC ALGORITHMS; NEURAL-NETWORKS; DRUG-DESIGN; PREDICTION; MODEL; OPTIMIZATION; PARAMETERS; SELECTION;
D O I
10.1111/j.1747-0285.2010.00953.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The support vector machine (SVM) and partial least square (PLS) methods were used to develop quantitative structure activity relationship (QSAR) models to predict the inhibitory activity of non-peptide HIV-1 protease inhibitors. Genetic algorithm (GA) was employed to select variables that lead to the best-fitted models. A comparison between the obtained results using SVM with those of PLS revealed that the SVM model is much better than that of PLS. The root mean square errors of the training set and the test set for SVM model were calculated to be 0.2027, 0.2751, and the coefficients of determination (R-2) are 0.9800, 0.9355 respectively. Furthermore, the obtained statistical parameter of leave-one-out cross-validation test (Q(2)) on SVM model was 0.9672, which proves the reliability of this model. The results suggest that TE2, Ui, GATS5e, Mor13e, ATS7m, Ss, Mor27e, and RDF035e are the main independent factors contributing to the inhibitory activities of the studied compounds.
引用
收藏
页码:506 / 514
页数:9
相关论文
共 44 条
[1]   Design and training of a neural network for predicting the solvent accessibility of proteins [J].
Ahmad, S ;
Gromiha, MM .
JOURNAL OF COMPUTATIONAL CHEMISTRY, 2003, 24 (11) :1313-1320
[2]   Prediction of 1H NMR chemical shifts using neural networks [J].
Aires-de-Sousa, J ;
Hemmer, MC ;
Gasteiger, J .
ANALYTICAL CHEMISTRY, 2002, 74 (01) :80-90
[3]  
[Anonymous], 1997, SUPPORT VECTOR MACHI
[4]  
[Anonymous], 2000, NATURE STAT LEARNING, DOI DOI 10.1007/978-1-4757-3264-1
[5]  
Appelt Krzysztof, 1993, Perspectives in Drug Discovery and Design, V1, P23, DOI 10.1007/BF02171654
[6]   Drug design by machine learning: support vector machines for pharmaceutical data analysis [J].
Burbidge, R ;
Trotter, M ;
Buxton, B ;
Holden, S .
COMPUTERS & CHEMISTRY, 2001, 26 (01) :5-14
[7]   Comparison of support vector machine and artificial neural network systems for drug/nondrug classification [J].
Byvatov, E ;
Fechner, U ;
Sadowski, J ;
Schneider, G .
JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES, 2003, 43 (06) :1882-1889
[8]  
Christianini N., 2000, INTRO SUPPORT VECTOR, P189
[9]   THE STRUCTURE AND FUNCTION OF THE ASPARTIC PROTEINASES [J].
DAVIES, DR .
ANNUAL REVIEW OF BIOPHYSICS AND BIOPHYSICAL CHEMISTRY, 1990, 19 :189-215
[10]   QSAR of novel hydroxyphenylureas as antioxidant agents [J].
Deeb, Omar ;
Youssef, Khairia M. ;
Hemmateenejad, Bahram .
QSAR & COMBINATORIAL SCIENCE, 2008, 27 (04) :417-424